228 related articles for article (PubMed ID: 20952513)
1. Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer.
Zhang B; Liu XX; He JR; Zhou CX; Guo M; He M; Li MF; Chen GQ; Zhao Q
Carcinogenesis; 2011 Jan; 32(1):2-9. PubMed ID: 20952513
[TBL] [Abstract][Full Text] [Related]
2. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2.
Lu J; He ML; Wang L; Chen Y; Liu X; Dong Q; Chen YC; Peng Y; Yao KT; Kung HF; Li XP
Cancer Res; 2011 Jan; 71(1):225-33. PubMed ID: 21199804
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2.
Ma DN; Chai ZT; Zhu XD; Zhang N; Zhan DH; Ye BG; Wang CH; Qin CD; Zhao YM; Zhu WP; Cao MQ; Gao DM; Sun HC; Tang ZY
J Hematol Oncol; 2016 Jan; 9():1. PubMed ID: 26733151
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.
Zhang JG; Guo JF; Liu DL; Liu Q; Wang JJ
J Thorac Oncol; 2011 Apr; 6(4):671-8. PubMed ID: 21270667
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells.
Dang X; Ma A; Yang L; Hu H; Zhu B; Shang D; Chen T; Luo Y
Cancer Genet; 2012 Mar; 205(3):113-23. PubMed ID: 22469510
[TBL] [Abstract][Full Text] [Related]
6. miR-26a suppresses tumour proliferation and metastasis by targeting metadherin in triple negative breast cancer.
Liu P; Tang H; Chen B; He Z; Deng M; Wu M; Liu X; Yang L; Ye F; Xie X
Cancer Lett; 2015 Feb; 357(1):384-392. PubMed ID: 25434799
[TBL] [Abstract][Full Text] [Related]
7. High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer.
Jansen MP; Reijm EA; Sieuwerts AM; Ruigrok-Ritstier K; Look MP; Rodríguez-González FG; Heine AA; Martens JW; Sleijfer S; Foekens JA; Berns EM
Breast Cancer Res Treat; 2012 Jun; 133(3):937-47. PubMed ID: 22094936
[TBL] [Abstract][Full Text] [Related]
8. Mutant p53 induces EZH2 expression and promotes epithelial-mesenchymal transition by disrupting p68-Drosha complex assembly and attenuating miR-26a processing.
Jiang FZ; He YY; Wang HH; Zhang HL; Zhang J; Yan XF; Wang XJ; Che Q; Ke JQ; Chen Z; Tong H; Zhang YL; Wang FY; Li YR; Wan XP
Oncotarget; 2015 Dec; 6(42):44660-74. PubMed ID: 26587974
[TBL] [Abstract][Full Text] [Related]
9. The Antitumor Effect of Metformin Is Mediated by miR-26a in Breast Cancer.
Cabello P; Pineda B; Tormo E; Lluch A; Eroles P
Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27517917
[TBL] [Abstract][Full Text] [Related]
10. MiR-630 suppresses breast cancer progression by targeting metadherin.
Zhou CX; Wang CL; Yu AL; Wang QY; Zhan MN; Tang J; Gong XF; Yin QQ; He M; He JR; Chen GQ; Zhao Q
Oncotarget; 2016 Jan; 7(2):1288-99. PubMed ID: 26595523
[TBL] [Abstract][Full Text] [Related]
11. miR-26a promoted by interferon-alpha inhibits hepatocellular carcinoma proliferation and migration by blocking EZH2.
Wang G; Sun Y; He Y; Ji C; Hu B; Sun Y
Genet Test Mol Biomarkers; 2015 Jan; 19(1):30-6. PubMed ID: 25494962
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of microRNA-26a is associated with metastatic potential and the poor prognosis of osteosarcoma patients.
Song QC; Shi ZB; Zhang YT; Ji L; Wang KZ; Duan DP; Dang XQ
Oncol Rep; 2014 Mar; 31(3):1263-70. PubMed ID: 24452597
[TBL] [Abstract][Full Text] [Related]
13. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms.
Koh CM; Iwata T; Zheng Q; Bethel C; Yegnasubramanian S; De Marzo AM
Oncotarget; 2011 Sep; 2(9):669-83. PubMed ID: 21941025
[TBL] [Abstract][Full Text] [Related]
14. MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells.
Erdmann K; Kaulke K; Rieger C; Salomo K; Wirth MP; Fuessel S
J Cancer Res Clin Oncol; 2016 Nov; 142(11):2249-61. PubMed ID: 27562865
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-30a suppresses breast tumor growth and metastasis by targeting metadherin.
Zhang N; Wang X; Huo Q; Sun M; Cai C; Liu Z; Hu G; Yang Q
Oncogene; 2014 Jun; 33(24):3119-28. PubMed ID: 23851509
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-26a inhibits proliferation by targeting high mobility group AT-hook 1 in breast cancer.
Zhao XX; Yuan QZ; Mu DP; Sun DW; Bo QA; Pan GZ; Li GQ; Cui T; Ding PP; You FP; Hao L; Wang MX; Zhang J
Int J Clin Exp Pathol; 2015; 8(1):368-73. PubMed ID: 25755724
[TBL] [Abstract][Full Text] [Related]
17. MiR-153 inhibits epithelial-mesenchymal transition by targeting metadherin in human breast cancer.
Li W; Zhai L; Zhao C; Lv S
Breast Cancer Res Treat; 2015 Apr; 150(3):501-9. PubMed ID: 25794773
[TBL] [Abstract][Full Text] [Related]
18. Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the Polycomb Ezh2 methyltransferase.
Derfoul A; Juan AH; Difilippantonio MJ; Palanisamy N; Ried T; Sartorelli V
Carcinogenesis; 2011 Nov; 32(11):1607-14. PubMed ID: 21828058
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-320a inhibits breast cancer metastasis by targeting metadherin.
Yu J; Wang JG; Zhang L; Yang HP; Wang L; Ding D; Chen Q; Yang WL; Ren KH; Zhou DM; Zou Q; Jin YT; Liu XP
Oncotarget; 2016 Jun; 7(25):38612-38625. PubMed ID: 27229534
[TBL] [Abstract][Full Text] [Related]
20. MiR-26a inhibits proliferation and migration of breast cancer through repression of MCL-1.
Gao J; Li L; Wu M; Liu M; Xie X; Guo J; Tang H; Xie X
PLoS One; 2013; 8(6):e65138. PubMed ID: 23750239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
